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Alpha-synuclein accumulation in intracellular inclusions, oxidative stress and microglia-mediated
inﬂammation in the substantia nigra are crucial events in the pathogenesis of Parkinson’s disease
(PD). Poly (ADP-ribose) polymerase-1 (PARP1), a DNA-binding enzyme and transcriptional regulator,
plays an important role in modulating the cellular response to oxidative stress, inﬂammatory stimuli, and
in apoptotic cell death. Inhibition of PARP1 results in signiﬁcant neuroprotection in PD animal models;
moreover PARP1 has a physiological role in the regulation of alpha-synuclein expression. A previous
study had demonstrated that variants located within the PARP1 gene promoter reduce the risk of PD and
delay the disease age at onset. In light of these data, we carried out an association study to investigate
whether variability within this gene is associated with PD risk and disease age at onset in an Italian
cohort composed of 600 PD patients and 592 healthy controls. To this purpose, we used a comprehensive
tag SNP approach spanning the entire gene and the upstream and downstream regions. We did not
detect any signiﬁcant association of the PARP1 gene with PD either at genotypic or haplotypic level; none
of the 11 genotyped SNPs was signiﬁcantly associated with PD age at onset. We conclude that, despite
previous evidence, PARP1 is not a susceptibility gene for PD in our population.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Parkinson’s disease (PD) is a debilitating neurological disorder
characterized clinically by bradykinesia, resting tremor, rigidity,
and postural instability with a therapeutic response to levodopa.
The disease is pathologically characterized by the loss of dopami-
nergic neurons in the substantia nigra pars compacta (SNpc) and
the presence of intracellular inclusions known as Lewy bodies,
which are composed primarily of alpha-synuclein protein aggre-
gates. There is accumulating evidences that hereditary factors play
a signiﬁcant role in the onset of PD [1]. In addition to the rare causal
mutations, which have provided us with many molecular clues to
elucidate the etiology of PD, also gene variants may promote
pathophysiological mechanisms, thereby affecting the risk to
develop sporadic PD. For instance, variability in the length of
a complex repeat sequence within the SNCA gene promoter (NACP-
Rep1) has been shown to affect risk of PD across populationsx: þ39 039 2332449.
ghina).
-NC-ND license.worldwide [2], presumably via mechanisms of modulation of
alpha-synuclein expression.
Poly (ADP-ribose) polymerase-1 (PARP1) is widely known as
part of the cellular defense against oxidative stress and repair
program due to its DNA-binding and ADP-ribosylation properties.
Poly(ADP-ribose) formation can inﬂuence also the action of tran-
scription factors, notably nuclear factor kappa B, which regulates
the expression of several inﬂammatory mediators such as cyto-
kines, chemokines, and adhesion molecules. However, excessive
PARP1 activation can promote neuronal death throughmechanisms
involving NADþ and ATP depletion and release of apoptosis
inducing factor (AIF) from the mitochondria to the nucleus. The
involvement of PARP1 in PD pathogenesis is supported by the
presence of abundant PARP-containing nuclei in the dopaminergic
neurons of the substantia nigra in PD [3]. Furthermore, PARP1 null
mice are resistant to the loss of dopaminergic neurons in the SNpc
following MPTP-induced neurotoxicity [4]. Finally, in vitro studies
have shown that PARP1 participates in the regulation of alpha-
synuclein expression by binding to the Rep1 polymorphic site
upstream of the SNCA gene [5].
In light of these data, we carried out an association study to
evaluate the role of the PARP1 gene as a susceptibility factor for PD.
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nucleotide polymorphisms (SNPs) spanning the entire PARP1 gene
at the single locus and haplotype level in a series of Italian PD
patients and unrelated controls.
2. Subjects and methods
2.1. Subjects
The study included 600 PD patients consecutively recruited from the outpatient
clinic for movement disorders at the Department of Neurology of San Gerardo
Hospital in Monza and at the Parkinson Institute in Milan. PD patients were diag-
nosed according to standard criteria [6]. Among patients, 45 (7.5%) reported a family
history of PD in at least a ﬁrst-degree or second-degree relative. Control population
consisted of 592 unrelated individuals, comprising healthy spouses and blood
donors. None of the controls had clinical evidence of neurological disease (as
assessed by neurological examination) or familial history of neurodegenerative
disease. Both patients and controls were Caucasians and the controls were
geographically matched to the cases. Informed consent for participation was
obtained from all subjects. Full ethical committee approval for this investigationwas
obtained.
2.2. Markers selection and genotyping
We used the LD-select algorithm, as implemented on the Seattle SNPs Genome
Variation Server (http://gvs.gs.washington.edu/GVS/) to identify tag SNPs at the
PARP1 locus based on data from the International HapMap Project Centre d’Etude du
Polymorphism Humain collection (CEU) population (http://www.hapmap.org). The
linkage disequilibrium (LD) r2 threshold for bins was 0.80, theminor allele frequency
cut-off >5%, and the region covered included 10 kb of upstream sequence (50end)
and 2 kb of downstream sequence (3’end). Eight tag SNPs were selected (rs8679,
rs3219142, rs1136410, rs3219123, rs3219110, rs1805410, rs1805414, rs3219053)
which captured a minimum of 85% of the genetic variation across the gene. More-
over, we genotyped one SNP ﬂanking the 30UTR (rs12567614), one intra-genic SNP
(rs1805405) shown to be haplotype tagging in a previous study [7] and one SNP in
the 50UTR region (rs907187). Table 1 highlights the genomic positions and type of
the genotyped markers.
Genomic DNAwas extracted from peripheral venous blood using a Qiagen Blood
kit (Qiagen, Milan, Italy). SNPs were typed using the GoldenGate Assay on VeraCode
microbeads (Illumina San Diego, CA, USA). The genotyping call rate for the studied
SNPs was in the range of 97e100%. Goodness of ﬁt of the genotype frequencies to
HardyeWeinberg expected proportions in control subjects was examined.
2.3. Data analysis
Chi-square tests were used to compare gender distribution, and genotype
frequencies between patients and controls and to test for deviation from Hardy-
Weinberg equilibrium. Student’s t-test was used to assess differences in age
between the two groups. We used logistic regression analysis to test for association
between the PARP1 gene selected variants and PD risk. The estimated odds ratios
(ORs) and relative 95% conﬁdence intervals (95% CI) were adjusted for gender and
age at enrollment. We performed analyses assuming autosomal dominant and
autosomal recessive models of inheritance. We also performed genetic analyses
testing a log-additive model in which genotype was categorized by three levels (0, 1
and 2, representing number of variant alleles), in order to assess the impact of each
additional copy of the risk allele on the odds of PD.
Analyses were performed for subjects overall and stratiﬁed by family history of
PD, age at study (divided in quartiles), and gender. The association of each geneticTable 1
Overview of location and type of the genotyped SNPs.
SNP id Genome position
(bp)a
Allele 1 Allele 2 Type of variant
rs12567614 224611043 C T Downstream
rs8679 224615177 T C 30UTR SNP
rs3219142 224618691 C T Intronic SNP
rs1136410 224621925 T C Coding-nonsynonymous
rs3219123 224621971 C T Intronic SNP
rs3219110 224624501 A G Intronic SNP
rs1805410 224635288 A G Intronic SNP
rs1805414 224639987 T C Coding-synonymous
rs3219053 224641177 G A Intronic SNP
rs1805405 224646644 C A Intronic SNP
rs907187 224662270 G C 50UTR SNP
Allele 1¼major frequency allele; allele 2¼minor frequency allele.
a Base position according to NCBI genome build 36.variant with age at onset of PD was assessed using Cox proportional hazard models,
adjusted for gender. For each genetic variant, we calculated a hazard ratio (HR),
a 95% CI, and a two-tailed P-value. We performed similar analyses of age at onset of
PD in men and women separately. All the analyses were performed using SPSS v. 16.
PARP-1 inter-SNPs LD measures (D0 , r2) were calculated using Haploview soft-
ware version 4.1 (http://www.broad.mit.edu/mpg/haploview/) for the set of control
samples.
We also used Haploview to reconstruct haplotypes and to assess the association
of the inferred haplotypes with PD. Haplotypes with inferred frequencies <0.01
were excluded from the analysis. The level of signiﬁcance was set at 0.05. Power
calculations were carried out using the Quanto software version 1.2.3. Results
The demographic data for the 600 PD patients were as follows:
mean age at study was 65.15 9.11 years (range 32e89), mean age
at onset of symptoms was 57.28 10 years (range 27e87). There
were 319 men and 281 women (male-female ratio 1.13:1). The 592
control subjects consisted of 308 males and 284 females; their
mean age at examination was 64.15 8.5 years (range 37e90).
There was no statistically difference in the age at study and gender
between patients and controls (p> 0.05).
The control genotype distributions were in agreement with the
HardyeWeinberg (HW) equilibrium (HW p-value >0.05) for all
except one marker (rs3219123, HW p-value¼ 0.005), which was
therefore excluded from further analyses. The allele frequencies of
the remaining 10 polymorphisms showed close similarity to Hap-
Map CEU data. All the considered SNPs showed a minor allele
frequency (MAF) over 5%. Fig. S1 shows the LD map for the PARP1
gene generated using Haploview. Some markers throughout the
gene showed evidence for linkage disequilibrium (LD); in partic-
ular, two SNPs pairs (rs3219053ers1805405 and rs907187ers1136
410) proved to be in complete or almost complete LD (r2¼1 and
r2¼ 0.95 respectively), therefore the non-tagging SNP of each
couple (rs1805405 and rs907187) was removed from the subse-
quent association analysis.
Table 2 lists the estimated ORs and associated 95% CIs from the
association analysis between each SNP and PD, assuming auto-
somal dominant, autosomal recessive and log additive models of
inheritance. Neither SNP was signiﬁcantly associated with PD
overall or in strata deﬁned by age at study, gender and family
history (data not shown).
Furthermore, we tested the possible association between all the
different combinations of alleles at the eight polymorphic loci with
PD. Six common haplotypes (CCCTAATG, CTTTGATG, TTCTAACA,
CTCTGGTG, TTCCAACG, TTCTGATG) and several rare ones (with
frequency< 5%) were inferred, and rare haplotypes were excluded
in the association analyses. None of the common haplotypes was
associated with overall risk for PD (global haplotype association p-
value¼ 0.36). Finally, in analyses restricted to PD cases, neither SNP
was signiﬁcantly associated with PD age at onset (data not shown).4. Discussion
Our results suggest that, despite the strong biological plausi-
bility, PARP1 is not a susceptibility locus for PD in our population.
The human PARP1 gene consists of 23 exons spanning 43 kb and has
been localized to chromosome 1q41eq42. To date, no other asso-
ciation studies using a comprehensive tag SNP (or comparable)
approach have been published on this gene in PD. The recently
launched website PDGene (http://www.pdgene.org/), which
systematically reviews genetic association studies of PD, conﬁrms
that information regarding the association of PARP1 with PD is still
lacking, with the single exception of a caseecontrol study
comprising 146 PD patients and 161 controls which showed that
variants located within the PARP1 gene promoter reduce risk of PD
Table 2
Single markers frequencies and association analyses with risk of PD
Genotypea frequency, n (%) Trend modelb Dominant model Recessive model
1/1 1/2 2/2 OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
rs12567614
Cases 211 (35.3) 295 (49.3) 92 (15.4) 1.02 (0.86e1.20) 0.83 1.09 (0.86e1.39) 0.46 0.91(0.67e1.25) 0.58
Controls 221 (37.5) 272 (46.1) 97 (16.4)
rs8679
Cases 322 (53.7) 234 (39.1) 43 (7.2) 0.97 (0.81e1.16) 0.75 0.95 (0.75e1.19) 0.65 1.02 (0.65e1.59) 0.92
Controls 311 (52.7) 238 (40.3) 41 (7)
rs3219142
Cases 404 (67.5) 180 (30) 15 (2.5) 1.02 (0.83e1.26) 0.86 1.09 (0.86e1.40) 0.47 0.64 (0.33e1.23) 0.17
Controls 410 (69.4) 158 (26.7) 23 (3.9)
rs1136410
Cases 456 (76) 135 (22.5) 9 (1.5) 0.87 (0.69e1.11) 0.26 0.87 (0.67e1.13) 0.29 0.77 (0.32e1.87) 0.56
Controls 433 (73.2) 147 (25) 11 (1.8)
rs3219110
Cases 213 (35.5) 275 (45.8) 112 (18.7) 0.98 (0.84e1.15) 0.81 0.96 (0.75e1.22) 0.73 1 (0.74e1.34) 0.98
Controls 202 (34.3) 278 (47.1) 110 (18.6)
rs1805410
Cases 434 (72.3) 145 (24.2) 21 (3.5) 1.01 (0.82e1.26) 0.9 1.01 (0.78e1.3) 0.96 1.09 (0.58e2.04) 0.8
Controls 426 (72) 147 (24.8) 19 (3.2)
rs1805414
Cases 275 (46) 262 (43.8) 61 (10.2) 1.07 (0.90e1.27) 0.45 1.15 (0.92e1.45) 0.22 0.93 (0.64e1.36) 0.72
Controls 292 (49.4) 236 (40) 63 (10.6)
rs3219053
Cases 395 (66) 186 (31) 19 (3) 1.20 (0.97e1.49) 0.1 1.23 (0.97e1.57) 0.09 1.24 (0.62e2.47) 0.54
Controls 416 (70.3) 161 (27.2) 15 (2.5)
The estimated odds ratios (ORs) and relative 95% conﬁdence intervals (95% CI) were adjusted for gender and age at enrollment.
a Allele 1 and allele 2 for each marker are speciﬁed in Table 1.
b The OR is computed for an increase of 1 minor allele.
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the tagging SNPs genotyped in the present study included a 10-kb
region upstream of the 5’end of the gene. The presence of potential
promoter activities for the PARP1 gene has been demonstrated up
to 1790 bp from the transcription initiation site by chloramphenicol
acetyltransferase assay [9].
Our negative ﬁndings are consistent with those from genome-
wide association studies (GWAs). Using the NEI/NCBI dbGAP data-
base (http://www.ncbi.nlm.nih.gov/), we spotted that some of the
SNPs genotyped in our study were contained in two previous GWAs
[10,11], which included three (rs1136410, rs1805410, rs1805414)
and two (rs1136410, rs1805410) PARP1 variants respectively.
However, both studies failed to identify any signiﬁcant association
between those SNPs and PD after correction for multiple testing (p-
values> 0.30).
Our study has some strengths: patients and controls came from
the same geographical area; diagnosis of PD was made by experi-
enced neurologists specialized in movement disorders; genotyping
errors were avoided using duplicate samples; many markers were
tested to assure a true association. For the association testing, we
also considered multiple genetic models, adjusted our analyses for
possible confounders (gender and age at study), and stratiﬁed our
sample for multiple variables (age at study, gender, familiarity) to
explore possible effect modiﬁcations. We genotyped haplotype
tagging SNPs, which ensures that all of the common variability
within a region of LD is surveyed in a disease association study.
Finally, the sample size employed and the minor allele frequency of
the selected SNPs provided sufﬁcient statistical power for the main
effect analyses. Assuming the population susceptibility allele
frequency to be the values observed in controls and a population
prevalence of 0.02, our study had 80% power (alpha¼ 0.05) to detect
ORs as small as 1.3 (or 0.77 or smaller) for the SNP with the highest
MAF, and as small as 1.42 (or 0.67 or smaller) for the SNP with the
lowest MAF under an additive model of inheritance. While the
current study has sufﬁcient power to detect ORs greater than 1.3, we
cannot, however, exclude the possibility that low frequency alleleswithin PARP1 may exert an effect on lifetime risk for PD or disease
age at onset. Moreover, these data cannot rule out the presence of
a genetic association between PARP1 and PD in other populations;
replication of the present study is required to clarify this issue.
Despite our data argue for a lack of association between PARP1
and PD in our population, it is still possible that this gene plays
a minor role in the susceptibility to the disease. Additional func-
tional as well as association studies investigating gene-gene inter-
actions are required to elucidate this issue, and it remains possible
that PARP1 variability may affect disease progression or the
susceptibility to develop PD non-motor symptoms.
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